Information  X 
Enter a valid email address

Warpaint London PLC (W7L)

  Print      Mail a friend

Tuesday 29 January, 2019

Warpaint London PLC

Trading Update

RNS Number : 3305O
Warpaint London PLC
29 January 2019
 

29 January 2019

Warpaint London plc

("Warpaint London" or the "Company")

Trading Update

 

Warpaint London plc (AIM: W7L), the specialist supplier of colour cosmetics and owner of the W7 and Technic brands, is pleased to provide a trading update in respect of the financial year ended 31 December 2018.

Subject to audit, the Company expects to report revenue of £48.5 million and adjusted profit before tax* of £8.25 million for the year ended 31 December 2018.

The Company expects to report its audited results for the year ended 31 December 2018 in April 2019.

*Adjusted profit before tax excludes amortisation in connection with acquisitions, share-based payment charges and exceptional items

 

Enquiries:

Warpaint London PLC    

Sam Bazini - Joint Chief Executive Officer

Eoin Macleod - Joint Chief Executive Officer

Neil Rodol - Chief Financial Officer

c/o IFC

 

 

Stockdale Securities Limited (Nominated Adviser and Broker)

Antonio Bossi- Corporate Finance

Fiona Conroy - Corporate Broking

 

020 7601 6100

 

IFC Advisory Limited (Financial PR & IR)

Tim Metcalfe

Heather Armstrong

Florence Chandler

 

020 3934 6630

 

 

 

Warpaint London plc

 

Warpaint London is a colour cosmetics business, based in Iver, Buckinghamshire. It is made up of two divisions: close-out and own-brand.  The second and larger own-brand division primarily consists of the Group's flagship brand, W7, together with the Technic, Body Collection and Man'stuff brands acquired through the acquisition of Retra Holdings in 2017.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TSTSEWFAAFUSESF

a d v e r t i s e m e n t